ViaCyte competitors

H has experience at UOP and has worked as Managing Dir:Korea & China at CABOT MICROELECTRONICS CORP, President/CEO at CABOT MICROELECTRONICS CORP, and Board Member at CABOT MICROELECTRONICS CORP. He attended Kellogg Graduate School of Management, Purdue University, and Northwestern University.

Philip Toleikis is a President/CEO at Sernova Corp and Board Member at Sernova Corp and is based in Vancouver, British Columbia, Canada. He has worked as President at PMToleikis&Associates Consulting, Inc. and VP at Surgical Specialties Corporation. Philip works or has worked as Vice President at ANGIOTECH PHARMACEUTICALS INC. He studied at University of British Columbia between 1990 and 1995, University of Michigan between 1982 and 1985, and University of Vermont between 1973 and 1976.

Cynthia Bamdad is a CEO at Minerva Biotechnologies and is based in Boston, Massachusetts. She has worked as Director at Pharmacyclics and CSO Clinical Micro Sensors, now Genmark at Minerva Biotechnologies. Cynthia works or has worked as BOARD MEMBER at Schl of Social Science, BOARD MEMBER at Urban Affairs and Public Policy, and BOARD MEMBER at Northeastern University. She attended Harvard University between 1992 and 1997 and Northeastern University.

Angelo Moesslang was named Chief Financial Officer of Fresenius Medical Care North America in August of 2010. He relocated to the Boston area from his native Germany. He began his career with Fresenius Medical Care in Germany in 1995, and held a variety of positions, including: Head of Investor Relations, Vice President of Business Development and Regional Director of NephroCare in Asia Pacific based in Hong Kong, and most recently, Chief Financial Officer of EAMELA (Europe, Africa, Middle East, Latin America). Prior to joining Fresenius, Angelo served as a scientific assistant to the faculty of Business Administration of the University of Stuttgart Hohenheim. He holds a Doctorate in Business Administration from University Stuttgart Hohenheim, and a Graduate Degree in Economics from Ludwigs-Maximilians University in Munich. In his leisure time, Angelo and his wife enjoy traveling, listening to a variety of music, exploring the Boston area, and especially enjoy entertaining friends with good food, wine and conversation.

Crystal Nyitray is a CEO & Founder at Encellin and is based in San Francisco, California. She has worked as PHD at UCSF, Student Teacher at CalTeach, and Undergraduate Researcher at UC Santa Cruz. Crystal attended UC Santa Cruz between 2005 and 2009 and UCSF between 2009 and 2015.

Bastiano Sanna, Ph.D., joined Vertex in 2019 and is the company’s Executive Vice President, Chief of Cell and Genetic Therapies. In this role, Dr. Sanna is responsible for advancing research, development and manufacturing for all of Vertex’s cell and genetic therapy programs, including hemoglobinopathies, Duchenne muscular dystrophy, myotonic dystrophy type 1 and type 1 diabetes. He will also oversee the future Vertex Cell and Genetic Therapies research site, which is expected to open in 2021 at Innovation Square in Boston’s Seaport District. Dr. Sanna was previously the CEO of Semma Therapeutics, which was acquired by Vertex in 2019. Under his leadership, Semma’s pioneering work to develop cell therapy treatments for those living with type 1 diabetes significantly advanced. Prior to Semma, Dr. Sanna was Chief Operating Officer at Magenta Therapeutics, where he was responsible for operations, finance, clinical development and program management. Prior to Magenta, Dr. Sanna served on the leadership team of Novartis’ Cell and Gene Therapy Unit as the Global Program Head of Stem Cell Transplant and early programs, where he oversaw clinical, regulatory, CMC and commercial aspects of programs in bone marrow transplant and CAR-T cell therapies. He also served as Global Head of Strategic Planning and Portfolio Management at the Novartis Institutes for BioMedical Research, where he was responsible for the global portfolio management of all Novartis’ research programs, from discovery through Phase II across all disease areas. Dr. Sanna received a Ph.D. in Biotechnology from the University of Sassari.

Christof Westenfelder is a Founder, CEO & MD at SymbioCellTech.

Paul Woods is the Chairman, Chief Executive Officer, and President of Algenol Biofuels. Algenol's Direct to Ethanol® Technology targets producing ethanol using proprietary algae, sunlight, non-arable land and carbon dioxide with operating costs of $1.20 per gallon, and production rates of 9,000 gallons of ethanol per acre per year. Waste algae is then processed by hydrothermal liquefaction and HT in gasoline, diesel, and jet fuel for an additional 1,300 gallons. Paul invented the Direct to Ethanol® Technology in 1984 while attending the University of Western Ontario near Toronto, Canada. Woods and Algenol currently hold 27 patents and have 51 patents pending. Algenol currently employs 120 employees in Lee County, Florida and 40 employees in Germany.